265 related articles for article (PubMed ID: 7803786)
1. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy.
Falini B; Pileri S; Pizzolo G; Dürkop H; Flenghi L; Stirpe F; Martelli MF; Stein H
Blood; 1995 Jan; 85(1):1-14. PubMed ID: 7803786
[No Abstract] [Full Text] [Related]
2. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4).
Horn-Lohrens O; Tiemann M; Lange H; Kobarg J; Hafner M; Hansen H; Sterry W; Parwaresch RM; Lemke H
Int J Cancer; 1995 Feb; 60(4):539-44. PubMed ID: 7530238
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry of Hodgkin and non-Hodgkin lymphomas with emphasis on the diagnostic significance of the BNH9 antibody reactivity with anaplastic large cell (CD30 positive) lymphomas.
Carbone A; Gloghini A; Volpe R
Cancer; 1992 Dec; 70(11):2691-8. PubMed ID: 1330287
[TBL] [Abstract][Full Text] [Related]
4. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.
Ansell SM; Horwitz SM; Engert A; Khan KD; Lin T; Strair R; Keler T; Graziano R; Blanset D; Yellin M; Fischkoff S; Assad A; Borchmann P
J Clin Oncol; 2007 Jul; 25(19):2764-9. PubMed ID: 17515574
[TBL] [Abstract][Full Text] [Related]
6. MDX-060. Medarex.
Hu XF; Xing PX
Curr Opin Investig Drugs; 2005 Dec; 6(12):1266-71. PubMed ID: 16370393
[TBL] [Abstract][Full Text] [Related]
7. A sinusoidal large cell lymphoma with expression of CD30, CD15, and multiple B-cell antigens: a classical Hodgkin lymphoma with sinusoidal infiltrating pattern or a sinusoidal CD30 positive large B-cell lymphoma with CD15?
Wang E; Foo WC; Huang Q
Leuk Lymphoma; 2010 Jun; 51(6):1148-51. PubMed ID: 20443679
[No Abstract] [Full Text] [Related]
8. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.
Gruss H-J ; Herrmann F
Leuk Lymphoma; 1996 Feb; 20(5-6):397-409. PubMed ID: 8833395
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor T-cell therapy targeting CD30 in Hodgkin lymphoma.
Savoldo B
Clin Adv Hematol Oncol; 2021 Jan; 19(1):24-26. PubMed ID: 33493145
[No Abstract] [Full Text] [Related]
10. CD30-positive cutaneous anaplastic large cell lymphoma with ichthyosis acquisita.
Zamolo G; Gruber F; Bosner A; Cabrijan L; Petković M; Jonjić N
Tumori; 1999; 85(1):71-4. PubMed ID: 10228503
[TBL] [Abstract][Full Text] [Related]
11. Sequential development of Hodgkin's disease and CD30+ diffuse large B-cell lymphoma in a patient with MALT-type lymphoma: evidence of different clonal origin of single microdissected Reed-Sternberg cells.
Parrens M; Vergier B; Fitoussi O; Lahet C; Belleannee G; Marit G; Dubus P; de Mascarel A; Delfau-Larue MH; Merlio JP
Am J Surg Pathol; 2002 Dec; 26(12):1634-42. PubMed ID: 12459631
[TBL] [Abstract][Full Text] [Related]
12. Mediastinal large B-cell lymphoma vs classic Hodgkin lymphoma.
Chadburn A; Frizzera G
Am J Clin Pathol; 1999 Aug; 112(2):155-8. PubMed ID: 10439794
[No Abstract] [Full Text] [Related]
13. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen.
Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
J Immunother; 1999 Nov; 22(6):473-80. PubMed ID: 10570745
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotypic and molecular analyses of acquired immune deficiency syndrome-related and Epstein-Barr virus-associated lymphomas: a comparative study.
Carbone A; Dolcetti R; Gloghini A; Maestro R; Vaccher E; di Luca D; Tirelli U; Boiocchi M
Hum Pathol; 1996 Feb; 27(2):133-46. PubMed ID: 8617454
[TBL] [Abstract][Full Text] [Related]
15. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
[TBL] [Abstract][Full Text] [Related]
16. Lymphoma: 4 big questions.
Eisenstein M
Nature; 2018 Nov; 563(7731):S55. PubMed ID: 30429571
[No Abstract] [Full Text] [Related]
17. CD30, Th2 cytokines and HIV infection: a complex and fascinating link.
Del Prete G; Maggi E; Pizzolo G; Romagnani S
Immunol Today; 1995 Feb; 16(2):76-80. PubMed ID: 7888070
[TBL] [Abstract][Full Text] [Related]
18. The value of anti-CD30 CAR T cells in Hodgkin lymphoma.
Veyri M
Lancet Haematol; 2024 May; 11(5):e314-e316. PubMed ID: 38555922
[No Abstract] [Full Text] [Related]
19. Clinicopathologic features and prognostic significance of CD30 expression in
Salas MQ; Climent F; Tapia G; DomingoDomènech E; Mercadal S; Oliveira AC; Aguilera C; Olga G; Moreno Velázquez M; Andrade-Campos M; Encuentra M; Fernández de Sevilla A; Sureda A; Sancho JM; González-Barca E
Biomarkers; 2020 Feb; 25(1):69-75. PubMed ID: 31752540
[No Abstract] [Full Text] [Related]
20. CD30-positive malignant lymphomas: time for a change of management?
Engert A
Haematologica; 2013 Aug; 98(8):1165-8. PubMed ID: 23904233
[No Abstract] [Full Text] [Related]
[Next] [New Search]
